We are 1-Methyl-3-phenoxybenzene CAS:3586-14-9 manufacturer and supplier in China, Pls send inquiry of to email@example.com of visit www.nbinno.com our official website should you have any interests
CAS No: 3586-14-9
Product Name: 1-Methyl-3-phenoxybenzene
3-methyl diphenyl ether
m-Methylphenyl phenyl ether
3-Methylphenyl phenyl ether
m-Tolyl Phenyl Ether
Density: 1.0±0.1 g/cm3
Boiling Point: 269.1±9.0 °C at 760 mmHg
Molecular Formula: C13H12O
Molecular Weight: 184.234
Flash Point: 110.8±14.4 °C
Exact Mass: 184.088821
Vapour Pressure: 0.0±0.5 mmHg at 25°C
Index of Refraction: 1.566
Appearance: Colorless oily liquid
Diphenyl ether: ≤0.8%
Intermediates of Pyrethrins CAS: 8003-34-7.
Be used as pesticide intermediate, mainly used in the synthesis of the insecticide Pyrethrins.
This product is used as an intermediate for pyrethroid insecticides, pressure-sensitive dyes and fragrances. It is a synthetic pyrethroid intermediate, mainly used to produce m-phenoxybenzaldehyde.
m-Phenoxytoluene, is a Diaryl ethers, which are important intermediate of the pesticides, and are widely used in synthesis of insecticides such as pyrethroids, and fungicides such as Difenoconazole.
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Related News: This leads to low numbers of one or more types of circulating blood cells, and to the need for blood transfusions. In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and may have genetic abnormalities associated with them.909709-42-8 The complete chemical and pharmaceutical industry chain consists of basic chemical raw materials, pharmaceutical intermediates, chemical raw materials and chemical preparations.Hidroquinona CAS:123-31-9 With the speeding up of review and approval, the number of approved innovative drugs in China is about to usher in a year of blowout.4-Hydrazinobenzenesulfonamide CAS:4392-54-5 With the speeding up of review and approval, the number of approved innovative drugs in China is about to usher in a year of blowout.The Company’s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line.